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Figure S1, related to Figure 1.  Relative position of T3.46 in the WT receptor showing the importance of this residue and how mutating it affects the receptor’s conformation. Figure 1 shows the physiological results of mutating this particular residue.

Table SIA-B, related to Figure 1.  Experimental evidence demonstrating the activity profiles of CB1 WT and two mutants, T3.46A and T3.46I.

Table SII, related to Figure 2.  Comparison of the conformations of the low-lying energy structures for the three receptors T3.46A, WT, and T3.46I.

Table SIII, related to Figures 2 and 3.  Comparison of the alterations in CB1 during activation with features seen in crystallized GPCRs.

Figure S2, related to Figure 3.  Effect of the amino acid at position 3.46 on the helical interactions in the human CB1 receptor. Mutating this particular residue forces the receptor conformation to change globally.

Table SIV, related to Figure 4.  Measurement of the thermal stability of CB1 WT, T3.46A, T3.46I, and T3.46A/R2.37A, and T3.46A/R2.37Q receptors. 

Figure S3, related to Figure 4.  Prediction and experimental verification of receptor stabilities.

Computational procedures provide details of the experiments.

Figure S4, related to Figures 2-4. Effect of the proline residue on the shapes of TM6 (A) and TM7 (B).  The proline residues change the OptHelix helices’s shape, which is highlighted here. These helices are used to build the five receptors discussed in this study.

Table SV, related to Experimental and Computational Procedures.  Constructing the WT, T3.46A, T3.46I receptors using first-based principles.
Section S1. Atomic view of residues

Position of the mutated residue T3.46:
The T3.46 residue (T210) is one helical turn above R3.50 (R214) (see Figure S1A), which is highly conserved among class A GPCRs. In the wild-type (WT) CB1 receptor, R3.50 makes a critical salt-bridge to D6.30 (D338). The crystal structures of bRho (1-10), sRho (11; 12), and hDD3R (13), thermally stabilized inactT1AR (14) and inactHA2AAR (15) mutants, and other experimental studies (16-19) have concluded that in the inactive form R3.50 forms a salt-bridge with D/E6.30 on the cytoplasmic end of TM6, leading to the proposal that this salt-bridge stabilizes the inactive form of the receptors and hinders their activation.
We predict that the T3.46 forms a hydrogen bond with the S2.45 (S158) residue (Figure S1B) in the CB1 WT receptor. This hydrogen bond is special because T3.46 is unique to the cannabinoid receptor. By mutating this particular residue to Ala or Ile, we break the hydrogen bond and change the interactions between the TM regions. The changes in the receptor conformation are reflected in the changes in experimental GTPS binding shown in Figure 1.

Section S2. Experimental Data:
The experimental results on the binding and functional profile of the CB1 WT and two mutant receptors (T3.46A and T3.46I) are shown in Tables SIA-B (21). The findings of that study indicate that the agonists bind with a higher affinity, relative to WT, to the T3.46I mutant receptor and with lower affinity, relative to WT, to the T3.46A mutant. Inverse agonists display exactly the opposite trend. The ligand binding affinity profiles for each receptor were consistent with the putative degree of activation, raising the possibility that this might arise from different conformations of the 7-helix bundle exhibited by each receptor. Table SIB, which shows how the G protein-coupling affects inverse agonist binding, is described in the main text.

Section S3. The ensemble of low-lying energy conformations of the seven-helix TM bundle
The predicted ensemble of low energy structures of WT CB1 and its two mutants, T3.46A and T3.46I, are shown in Table SIIA. Their corresponding salt-bridge patterns are shown in Table SIIB-D. We find that the orientations of some helices change dramatically upon mutation. Here we denote the angle about the helix axis as  (rotation) and the two angles defining the tilt as  (tilt) and  (sweep) as defined in Ref. (23). The average energy ranges are:
	T3.46A: -334.3 kcal/mol to -311.2 kcal/mol
	WT: -350.8 kcal/mol to -332.0 kcal/mol
	T3.46I: -317.1 kcal/mol to -289.9 kcal/mol 
And the backbone RMSD, with respect to the lowest energy structure, ranges are:
	T3.46A: 0.2 Å - 3.5 Å
	WT: 0.4 Å - 2.1 Å
	T3.46I: 0.9 Å - 2.4 Å
The lowest energy conformations for each receptor are structurally similar to one another as indicated by their RMSDs. For the crystallized GPCRs, their crystal resolution ranges from 1.80 Å (24) to 4.15 Å (25). All of the calculated RMSD values are either lower than or fall within the crystal resolution range indicating that x-ray crystallography could not distinguish the various low-lying energy conformations for a particular receptor. These predicted structures differ greatly from the x-ray crystal structure of inactT1AR (PDB ID: 2VT4) (22). Thus homology modeling would be ineffective for predicting CB1 receptor conformations, especially for the active states.

Section S4.  Comparison to crystallized GPCRs

Table SIII compares the differences we observe between our weakly constitutively active, WT, and highly constitutively active, T3.46I, models with those in four pairs of crystallographically characterized inactive and “active” GPCRs. There is a strong correlation between the trends in our models and those in the crystals. The few discrepancies involve TM7. In the HA2AR crystallized proteins, S7.42 and H7.43 move closer to TM3 by 2 Å (27). In contrast, we find that C7.42 of CB1 moves closer to TM2, not TM3, by 3.5 Å, while L7.43 moves outward, not inward, by 4.8 Å. However, movement of the HA2AR enables S7.42 and H7.43 to form new polar interactions with the agonist. Neither of these residues is conserved in CB1, and L7.43 is not able to make polar interactions.

Section S5. Homology Modeling
S5.1 Straight homology models cannot explain the functional effects of single-point mutations
Figure S2 shows the results of the amino acid substitution without altering the helix packing (a homology model). Figure S2A shows the homology model of WT based on T3.46A, obtained by mutating the A3.46 residue to T3.46. The larger side chain of the T3.46 residue clashes with the TM2 backbone and results in extremely unfavorable energies. Therefore, TM2 and/or TM3 must move to accommodate the T3.46 residue, affecting the packing of other five helices. Similarly, Figure S2B shows the homology model of T3.46I based on WT, obtained by mutating the T3.46 residue to I3.46. The larger Ile residue collides with S2.45. Thus, TM3 must shift to accommodate the presence of the larger side chain. However, it only moves slightly, sweeping away from TM2 by 15°. These helix movements cause large changes in the rest of the TM helix bundle in order to maximize favorable interactions, which cannot be captured by homology models even after relaxation by molecular dynamics methods.
S5.2 Comparison to Previous Homology Modeling Studies 
Initial studies by Reggio and co-workers used the bRho template to develop homology models of CB1 (30-33). Significantly kinked TM6 conformations (34) were added to the predicted 7-helix bundle forming (R3.50+D6.30) that had been observed in the crystallographically characterized structure of bRho. This predicted structure included another TM3+TM6 coupling between extracellular residues K3.28 and D6.58 (30). The CB1 active conformation was created by using activation hints from bRho and inactH2AR: TM6 was straightened, and TMs 3 and 6 were rotated counter-clockwise with respect to the extracellular side. These motions broke both TM3+TM6 couplings (30). 
A more recent model has used the inactH2AR crystallographically characterized structure as a homology template to provide secondary structure information. Only two salt-bridges were observed—one between R3.50 and D6.30 as in the models discussed above and another between K3.28 and D2.63 (35) rather than D6.58 as proposed from the bRho homology structure (30). In general, these previous models agree that the conserved (R3.50+D6.30) interaction is present in the constitutively active state. Shim’s 2010 review (36) proposes that the activation mechanism CB1 consists of the agonist binding to EC2, which causes this loop region to couple to the aromatic microdomain in TMs 5 and 7, thereby forcing W6.48 to undergo a toggle switch. This, in turn, causes a cascade of interactions between hydrophobic or polar residues in the intracellular direction resulting in the breakage of the (R3.50+D6.30) interaction (36). This mechanism needs to be experimentally verified.
None of the previous structures have implicated the TM2+TM6 coupling as being critical for the fully inactive CB1 receptor.

Section S6. Comparison of predicted relative stability of receptors with thermal denaturation experiments
S6.1 Predicted stabilities of the five receptors
We used the total energies from the GEnSeMBLE calculations as one component to determine the ensemble of low energy packings for the receptors. However, we cannot compare total energies for different mutants because of the different topology of atoms in the WT and mutants. Instead, Figure S3A shows the average interhelical energies of the ten lowest average energy conformations for each of the five receptors including the two double mutants. Each circle represents one protein conformation. These energies of the predicted conformations suggest that the T3.46A and T3.46A/R2.37Q mutants are the most stable; the WT and T3.46A/R2.37A receptor are less stable, while the T3.46I is least stable.


S6.2 Comparison of predictions to experimental thermal stability data
	To obtain an experimental measurement of the relative stabilities, we preformed thermal denaturation assays for the five receptors (Figure S3B and Table SIV) as described in Section S6.3 below. We find that the thermal denaturation for T3.46I leads to a melting temperature (Tm) of 58.8ºC, while WT denatures at Tm = 64.3ºC and T3.46A denatures at 71.2ºC. Our proposed double mutants denature at temperatures between that of T3.46A and WT. T3.46A/R2.37A denatures at 68.3ºC, and T3.46A/R2.37Q denatures at 67.8ºC. Thus, our predicted relative stabilities, described above, are in overall agreement with the thermal stability data. Indeed, Figure S3C shows good correlation between the Tm and the calculated lowest average interhelical energy with an R2 value of ~0.82.
S6.3. Measurement of receptor thermal stability 
Approximately 10 μg of membrane preparations from the WT, T3.46A, T3.46I, T3.46A/R2.37Q, or T3.46A/R2.37A receptor-expressing HEK293 cells were incubated at the specified temperature for 30 min. Control samples were kept on ice for 30 min. For every mutant, the different membrane aliquots were each heated at a single temperature ranging from 30C to 100C. After incubation, the samples were quenched on ice, re-homogenized, and added to TME buffer containing a near-saturating concentration of [3H]CP55940 (147.9 Ci/mmol, PerkinElmer Life Sciences, Boston, MA) for further incubation for 60 min at 30C. The radioligand was used at a concentration 10-fold above Kd for each receptor (20 nM, 4 nM, or 75 nM [3H]CP55940  for WT, T3.46I, and T3.46A receptors, respectively), as determined by saturation binding, to minimize the impact of any possible affinity change. Nonspecific binding was determined in the presence of 1 μM unlabeled ligand. Reactions were terminated by adding 250 μl of TME containing 5% BSA followed by filtration with a Brandel cell harvester through Whatman GF/C filter paper. Radioactivity was measured by liquid scintillation counting. Three independent thermal stability measurements were carried out each in duplicate. The data were analyzed by non-linear regression using GraphPad Prism Software (GraphPad Software Inc., San Diego, CA) to obtain the midpoint (apparent Tm) at 50 % loss of specific binding as described previously (37; 38).

Section S7.  Computational procedures

Step 1: Predicting the WT receptor structures
Part A: Predict transmembrane (TM) helix regions of the receptor

Based on the hydrophobic character of the human CB1 amino acid sequence, we predicted the transmembrane sequences using PredicTM, a method that we have developed.  Based on a BLAST (39) search with an E-value of 0.1, the first step in PredicTM, to human CB1, we found 1387 sequences of 7-helix proteins with sequence identities ranging in from 100% to 8.47%. Table SVA compares the sequence identities of the crystallized GPCR sequences to the human CB1 receptor sequence. The overall sequence identities to the seven crystal structures fall in the ~10-16% range with TM sequence identities ranging between ~16-28%. The human CB1 receptor lacks certain motifs common to other class A GPCRs such as the conserved proline in TM5 and a disulfide bond between TM3 and the second extracellular loop (EC2). Thus, homology modeling is not expected to be effective as demonstrated by the total energy comparison discussed in Step1 Part D. Moreover, our results show dramatic changes in TM orientations with just a single point mutation, invalidating the fundamental assumption in homology modeling. The other member of the human cannabinoid family, CB2, has a 32.42% sequence identity with human CB1 and a 52.59% sequence identity within the CB1 TM regions.

Our second step in PredicTM uses MAFFT (40) based on the ‘E-INS-i’ method, which performs a multiple sequence alignment of the sequences identified by the BLAST search. This is followed by using the Wimley-White octanol hydrophobicity scale (41), to assign a numeric hydrophobicity value to each amino acid position in the aligned sequence, where we average these values over the whole set of 1387 aligned amino acids from each sequence. Then, these raw averages are averaged over traveling windows ranging in size from 7, 9, 11 to 21 residues. These window sizes range from local sampling (7, 9, or 11 residues) to larger sampling (21 residues) to capture the hydrophobic character of the helix. The seven residue window corresponds to roughly two helix turns, while 21 is about the length of the full TM helix. Next, all eight traveling windows are averaged, so that each amino acid is assigned a single hydrophobicity value. These values for the human CB1 sequence are plotted (data not shown) to identify the seven obvious hydrophobic regions lying above the 0 baseline which we assume form seven TM helical domains spanning the hydrophobic lipid bilayer providing the length and the hydrophobic center for each TM domain. We assume that the midpoint of the hydrophobic region for each helix provides the buoyant centers of the TM domains, with all seven lying in the same plane at the center of the membrane.
This hydrophobic analysis provides the raw hydrophobic regions of the helices, but GPCR crystal structures of bRho (PDB ID: 1U19) (5) and hCXCR4 (PDB ID: 3ODU) (42) show that the hydrophobic helices can extend one or two turns out of the lipid bilayer into the solvent. To extend the hydrophobic regions of the helices, we developed a consensus helix capping using three secondary structure prediction servers: Porter Protein Secondary Structure Prediction Server (43; 44), APSSP2: Advanced Protein Secondary Structure Prediction Server (45; 46), and PSIPRED: Protein Prediction Server (47-49).

Part B: Optimize helix shapes for the seven TM segments using OptHelix
	Then to build and optimize the 3D structures of the TM domains, we use our OptHelix method. OptHelix performs a series of MD and energy minimizations to find the most stable structure of each individual helix. We first built a polyalanine helix matching the length of the predicted capped TM domains. Here the glycine and proline residues from the original sequence are mutated into the helices using SCREAM (Side Chain Rotamer Excitation Analysis Method), a side chain optimization program (50). Proline and glycine are known helix-breakers that affect the backbone structure (51-53). The backbones of these TM domains are minimized to a root-mean squared (RMS) force of 0.5 kcal/mol/Å or to a maximum of 1000 steps in order to describe the modification on the backbone structure caused by mutating alanines to prolines. Previous studies have shown that the serine and threonine residues can either enhance or decrease the kink by interacting with the proline or amide groups within one turn (54). Thus, we next mutate the appropriate Ala to Ser or Thr using SCREAM. Then we do “warm-up” MD (by heating in 50 K increments from 50 K to 250 K for 10 ps each with a 2 fs timestep for a total of 40 ps) separately for each of the seven helices to prevent distortions that may be caused by the original assignment of velocities. Finally we equilibrate with 300 K MD for 2 ns with a 2 fs timestep. Ignoring the first 0.5 ns, we save snapshots every 10 ps for a total of 150 snapshots. We then select the snapshot with the lowest potential energy and mutate all residues to the proper amino acid using SCREAM. The final structure is minimized to a RMS of 0.5 or for a maximum number of 100 steps.
	Figure S4 shows the OptHelix products for TMs 6 and 7. These helices contain proline residues, which impact the backbone shape by altering the bend, wobble, and face shift angles, as defined in Ref. (55) and indicated in the figure. The P6.50 residue (Figure S4A) causes the helix to bend 11.2°. The wobble angle, defined to be orientation of the post-proline portion of the helix with respect to the axis containing the proline’s alpha-carbon, is a significant -128.7°. The face shift is the angle between proline’s alpha-carbon and the vector between the alpha-carbons of the (i-3) and (i-4) residues away from proline indicating if the helix is over- or under-wound. The positive 48.1° face shift angle for P6.50 shows that the helix is under-wound.  P7.50 (Figure S4B) causes a less significant bend of only 6.7°. TM7’s wobble angle is at 167.5°, which is in the opposite direction than the one in TM6. The face shift angle is less significant in TM7 at 22.1°, but like TM6, this helix is under-wound.

Part C: Generate template for receptor bundle
	The seven optimized helices are then aligned to the experimental crystal templates inactT1AR (PDB ID: 2VT4). This template was chosen over the inactH2AR (PDB ID: 2RH1) template because our calculations gave lower energies for the inactT1AR bundles. The initial inactT1AR template provides initial values for the x, y positions and the , (tilt), , (sweep), and , (rotation) angles for each helix. The z position corresponds to the hydrophobic center determined in Part A, with all seven hydrophobic centers on the same midpoint plane. Then we perform an exhaustive sampling of what we consider to be a complete set of , , and  angles to find the low energy receptor conformations.

Part D: Create ensemble of orientations of seven helices
We have found that it is essential to rotate all seven helices simultaneously to find the optimum combinations. Thus considering 30° increments in  (which we found to be the minimum sampling size), there are 127 = 35.8 million combinations, all of which must be examined in order to select the optimum packings of the bundles. To enable a complete sampling of all these 35.8 million conformations to identify the ensemble of low-lying energy poses that might play a role in binding ligands and activation, we developed the BiHelix and ComBiHelix procedures (23).
The first step, BiHelix, independently considers just the 12 pairs of helices that are close enough to interact [1-2, 1-3, 1-7, 2-3, 2-4, 2-7, 3-4, 3-5, 3-6, 3-7, 4-5, 5-6, and 6-7]. For each of the 122=144 combinations of each pair, the side chains are optimized using SCREAM and energy minimized for 10 steps. Summing the total intra- and interhelical values from these 12*144=1728 pairwise interaction energies leads to an energy estimate for all 35.8 million receptor bundles. Then, CombiHelix selects the 1000 predicted combinations for the 7-helix bundle predicted to have the lowest energy (20) and constructs the entire receptor 7-helix bundle and evaluates the total energy bundle (using SCREAM to optimize the side chains and minimizing the energy for 10 steps). Ranking these 1000 bundles by their minimized total energy, we select the lowest energy bundle, as shown in the Table SVB. This bundle was chosen as the starting point for simultaneous optimization refinement of the tilt angles ( and ) while re-optimizing the  angles.
	In addition to the above predictions, we repeated this procedure using helices from a crystal homology model rather than products from OptHelix. This biased the calculations to match the helix shape of the crystallized GPCRs including, inactT1AR (PDB ID: 2VT4) (22), inactH2AR (PDB ID: 2RH1) (56), and inactHA2AAR (PDB ID: 3EML) (57). In each case we start with the crystal structure, remove the loops, mutate the residues to the target (WT CB1) sequence, extend or shrink the length of the helices to match those of the OptHelix helices, and use the new ones to sample all 35.8 million combinations of the  angles. The homology helices are the same length as the OptHelix helices, so we can compare the total energy of the receptors since they all have the same number of atoms. Table SVC shows the final energy comparison of the WT receptor built from various helices. The OptHelix helices produced the lowest energy helix bundle with a post-minimization energy value of -110.4 kcal/mol. The three cases with homologized helices range in energies of 15.9 to 109.6 kcal/mol, which are ~100-200 kcal/mol worse than that of the one with OptHelix helices. Furthermore, we find the homologized helices to be physically unreasonable because rimonabant-binding residues W5.43 and/or K3.28 (30; 32) are in positions that are not accessible to the binding site.
The lowest total energy ComBiHelix structure is used as the starting structure for further refinement in which the tilt angles (, ) are optimized simultaneously with . First the two terminal residues on each TM are replaced using SCREAM with alanine residues if they are one of the five charged residues. This alanization of the terminal residues eliminates the strong electrostatic interactions at the ends of the helices, which may bias the calculations of the side chain interaction energies. This alanization step must be done when allowing variations in the  and  angles along with variations in the  angle. In SuperBiHelix, the  and  angles are sampled over 30 in 15 increments, while the  is sampled over 10. With these ranges we consider (5*5*3)7=13.3x1012 or ~13 trillion packings from which we select the top 2000 based on lowest total SuperBiHelix combinations of pair-wise energies. These are built into full 7-helix bundles in SuperComBiHelix. Then we evaluate the full energy of each of these 2000 after optimizing side chains and minimizing the energy.

Part E.  Choose the lowest energy structures
From the 2000 best receptor bundles from SuperComBiHelix, we choose an ensemble of 10 low energy poses based on average energy rank. Here we use four ways to estimate the average energy. Two ways use the normal charged form of Asp, Glu, Lys, Arg, His, while the other two consider neutral forms for each of those residues. We also consider two ways to combine the energies. In addition to the total energy, we also consider only interhelical interactions (with either charged or neutralized residues). From studies over many systems for which we can compare to x-ray crystal structures, we find that ranking the structures using all four methods and averaging this ranking leads to the most reliable predictions. The all atom DREIDING force field is used for all energy calculations.

Step 2:  Predicting the T3.46A, T3.46I, T3.46A/R2.37A, and T3.46A/R2.37Q receptor structures

Mutate T3.46 residue into alanine or isoleucine and/or R2.37 into alanine or glutamine using SCREAM in the OptHelix helices

	To predict the ensemble of low-lying mutant structures, we use the same methodology as described for the WT receptor. Here the WT OptHelix helices built in Step1 Part A are used to generate the receptor bundle, but T3.46 in helix 3 is mutated into an alanine or an isoleucine and/or R2.37 in helix 2 is mutated into an alanine or glutamine using SCREAM. The subsequent steps are the same for the mutants as they are for the WT receptor (see Step 1), where full helix bundle conformational sampling is performed for each mutant.
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TABLES

Table SIA-B. related to Figure 1.  Experimental evidence (21) demonstrating the activity profiles of CB1 WT and two mutants, T3.46A and T3.46I.  (A) Binding properties of the inverse agonist rimonabant and the agonist (R)-(+)-WIN55212-2 for the T3.46I, WT, and T3.46A receptors.  (B) GTPS effect on inverse agonist rimonabant binding to CB1 T3.46A, WT, and T3.46I receptors. 

A
	vs. [3H]CP55940	vs. [3H]SR141716A
Ligand	WT Ki (nM)	T3.46I Ki (nM)	WT:T3.46I Ki ratio	WT Ki (nM)	T3.46A Ki (nM)	WT:T3.46A Ki ratio
(R)-(+)-WIN55212-2	73 ± 6	28.3 ± 3.5	3:1	68 ± 1	1440 ± 414	1:21
Rimonabant	7.5 ± 1.6	190 ± 11	1:25	7.2 ± 1.7	2.2 ± 0.4	3:1

B
Receptor	-GTPS: IC50 (nM)	+GTPS: IC50 (nM)
T3.46A	3.8 ± 0.5	4.3 ± 0.6
WT	8.0 ± 2.2	1.6 ± 2.6
T3.46I	450 ± 150	15 ± 2




Table SII, related to Figure 2.  Comparison of the conformations of the low-lying energy structures for the three receptors T3.46A, WT, and T3.46I.
(A)	Theta, , (tilt), phi, , (sweep), eta, , (rotation) angles and the backbone RMSD (Å) with respect to the lowest energy conformation of the ten lowest energy T3.46A, WT, and T3.46I receptors.  The inactT1AR crystal (PDB ID: 2VT4) (22) is the reference case. The poses were chosen according to their average energy rank, the average of the charged total energy rank, neutralized total energy rank, charged interhelical energy rank, and neutralized interhelical energy rank.
(B-D)  Salt-bridge patterns for the ten lowest energy structures of each receptor: T3.46A (B), WT (C), and T3.46I (D) receptors. 


A



B
T3.46A Structure #	R2.37+D3.49 salt-bridge	R2.37+D6.30 ionic lock	D2.63+K3.28 salt-bridge 	D3.49+K4.41 salt-bridge 	R3.50+D6.30 ionic lock 	R5.71+D6.30 salt-bridge	D6.58+K7.32salt-bridge
1	No	Yes	No	Yes	Yes	No	Yes
2	No	Yes	No	Yes	Yes	No	Yes
3	No	Yes	No	Yes	Yes	No	No
4	No	No	No	Yes	Yes	No	Yes
5	No	Yes	No	Yes	Yes	No	Yes
6	No	Yes	No	Yes	No	No	Yes
7	No	No	No	No	No	No	Yes
8	No	Yes	No	Yes	No	No	No
9	No	Yes	No	Yes	Yes	No	No
10	No	Yes	No	No	Yes	No	Yes
Consensus	No	Yes	No	Yes	Yes	No	Yes



C
WT Structure #	R2.37+D3.49 salt-bridge	R2.37+D6.30 ionic lock	D2.63+K3.28 salt-bridge 	D3.49+K4.41 salt-bridge 	R3.50+D6.30 ionic lock 	R5.71+D6.30 salt-bridge	D6.58+K7.32salt-bridge
1	Yes	No	Yes	Yes	No	No	Yes
2	Yes	No	Yes	Yes	Yes	No	Yes
3	Yes	No	Yes	Yes	Yes	No	Yes
4	Yes	No	Yes	Yes	Yes	No	Yes
5	Yes	No	Yes	Yes	No	No	Yes
6	Yes	No	Yes	Yes	No	No	Yes
7	Yes	No	Yes	Yes	Yes	No	Yes
8	Yes	No	Yes	Yes	Yes	No	Yes
9	Yes	No	Yes	Yes	Yes	No	Yes
10	Yes	No	Yes	Yes	Yes	No	Yes
Consensus	Yes	No	Yes	Yes	Yes	No	Yes



D
T3.46I Structure #	R2.37+D3.49 salt-bridge	R2.37+D6.30 ionic lock	D2.63+K3.28 salt-bridge 	D3.49+K4.41 salt-bridge 	R3.50+D6.30 ionic lock 	R5.71+D6.30 salt-bridge	D6.58+K7.32salt-bridge
1	No	No	Yes	No	Yes	No	No
2	Yes	No	Yes	No	No	No	No
3	Yes	No	Yes	No	No	Yes	No
4	Yes	No	Yes	No	No	Yes	No
5	Yes	No	Yes	No	No	Yes	No
6	Yes	No	Yes	No	No	No	No
7	Yes	No	Yes	No	No	No	No
8	Yes	No	Yes	No	No	Yes	No
9	Yes	No	No	No	No	Yes	No
10	Yes	No	Yes	No	No	Yes	No
Consensus	Yes	No	Yes	No	No	Yes	No



Table SIII, related to Figures 2 and 3.  Comparison of the alterations in CB1 during activation with features seen in crystallized GPCRs. The observed structural changes between the constitutively active WT and the fully active T3.46I are similar to what is observed in crystal structures.  We indicate the cases where the CB1 models show deviations (red) from the crystal models.

Crystallized GPCR	Crystallized GPCR portion	CB1 model portion	Change during activation of crystallized GPCRs	Change from WT-3 to T3.46I-4
bRho/bOps (26), HA2AAR (27)	TMs 1 – 4	TMs 1 – 4	Not much change	Not much change (except TM4)
bRho/bOps, HA2AAR	TMs 5 – 7	TMs 5 – 7	Large amount of movement	Large amount of movement
bRho/bOps	TM5	TM5 (M5.72)	Cytoplasmic end moves toward TM6 by 2 - 3 Å	Cytoplasmic end moves toward TM6 by 4.8 Å
bRho/bOps	TM6	TM6 (D6.25)	Cytoplasmic end moves outward by 6 – 7 Å	Cytoplasmic end moves outward by 6.6 Å
bRho/bOps	TM5 and TM6	TM5 and TM6	Become parallel to each other	Become parallel to each other
bRho/bOps	TM3 and TM6	TM3 and TM6	Broken ionic lock	Broken ionic lock
bRho/bOps	TM5 and TM6	TM5 and TM6	New salt-bridge	New salt-bridge
H2AR/nano-body (28)	E6.30	D6.30	Moves 11.4 Å	Moves 7.4 Å
H2AR/GS (29)	E6.30	D6.30	Moves 14.7 Å	Moves 7.4 Å
H2AR/nano-body	S5.46	V5.46	Moves inward by 2.1 Å	Moves inward by 2.2 Å
H2AR/GS	S5.46	V5.46	Moves inward by 1.8 Å	Moves inward by 2.2 Å
H2AR/nano-body	P5.50	L5.50	Moves inward by 1.4 Å	Moves inward by 2.2 Å
H2AR/GS	P5.50	L5.50	Moves inward by 1.6 Å	Moves inward by 2.2 Å
HA2AAR	W6.48	W6.48	Moves inward by 1.9 Å	Moves inward by 1.3 Å
HA2AAR	S7.42	C7.42	Moves closer to TM3 by 2 Å	Moves closer to TM2 by 3.5 Å
HA2AAR	H7.43	L7.43	Moves closer to TM3 by 2 Å	Moves away from TM3 by 4.8 Å
HA2AAR	N6.55	M6.55	Fixed	Moves by 0.9 Å
HA2AAR	TM6	TM6 (D6.25)	Cytoplasmic end moves outward by 3 – 4 Å	Cytoplasmic end moves outward by 6.6 Å
HA2AAR	NPxxY	N7.49	Moves inward by 4 – 5 Å	Moves inward by 3.5 Å
HA2AAR	Y7.53	Y7.53	Moves by 5 Å, rotameric switch	Moves by 4.0 Å, no rotameric switch

Table SIV, related to Figure 4.  Measurement of the thermal stability of CB1 WT, T3.46A, T3.46I, and T3.46A/R2.37A, and T3.46A/R2.37Q receptors.  Assays were carried out as described in experimental procedures. The apparent Tm (mean  S.E.M.) from thermal denaturation curves for each receptor was obtained from three individual experiments done in duplicate.
Receptor	Apparent Tm  (C)
T3.46A	71.4  1.8
T3.46A/R2.37A	68.3  0.9
T3.46A/R2.37Q	67.8  1.0
WT	64.5  1.1
T3.46I	58.9  0.5



Table SV, related to Experimental and Computational Procedures.  Constructing the WT, T3.46A, T3.46I receptors using first-based principles.
(A)	Comparison to the human CB1 receptor sequence of the overall sequence identity and TM sequence identity of human CB2 and crystallized GPCR sequences including HA2AAR, T1AR, H2AR, sRho, hDD3R, bRho, and hCXCR4.
(B)	Sampling rotation angles for CB1 receptors.  Optimized  (rotation), angles from the ComBiHelix program for the three receptors: T3.46A, WT, and T3.46I. The crystal inactT1AR (PDB ID: 2VT4) (22) is the reference case.
(C)	Energy comparison for CB1 receptors with OptHelix helices and homologized helices.  Optimized , (rotation), angles from the ComBiHelix analysis for the WT receptors with various helices: OptHelix helices aligned to crystal inactT1AR (PDB ID: 2VT4) template, homology inactT1AR (PDB ID: 2VT4) helices, homology inactH2AR (PDB ID: 2RH1) (56) helices, and homology inactHA2AAR (PDB ID: 3EML) (57) helices.


A
GPCR Name	Overall Sequence Identity (%)	TM Sequence Identity (%)
Human CB1 Receptor	100	100
Human CB2 Receptor	32.42	52.59
Turkey Beta 1 Adrenergic Receptor	15.89	28.45
Human A2A Adenosine Receptor	16.10	26.31
Human Beta 2 Adrenergic Receptor	14.19	24.65
Human D3 Dopamine Receptor	10.81	24.09
Bovine Rhodopsin Receptor	10.59	21.94
Human CXCR4 Receptor	9.96	18.57
Squid Rhodopsin Receptor	13.14	16.27

B
	 ()
Receptor	H1	H2	H3	H4	H5	H6	H7
T3.46A	-120	-150	0	0	-120	30	-90
WT	90	-60	0	0	-120	30	-120
T3.46I	150	-90	0	30	-120	0	-30



C
	 ()	PostMinE
Method	H1	H2	H3	H4	H5	H6	H7	(kcal/mol)
Gensemble—inactT1AR template	90	-60	0	0	-120	30	-120	-110.4
Homologized inactT1AR Helices	-30	0	0	-30	-120	0	90	108.1
Homologized inactH2AR Helices	0	0	0	0	0	0	90	15.9
Homologized inactHA2AAR Helices	0	0	0	-30	180	90	-120	109.6





Figure S1, related to Figure 1.  Relative position of T3.46 in the WT receptor.
(A)	Predicted structure of TM3 of human CB1 receptor’s helix 3.  Residues R3.50 and T3.46 (indicated) are on the same face of the helix, pointing into the center of the receptor bundle.
(B)	Atomic view of the interaction between T3.46 and S2.45 in WT CB1.  Interaction between T3.46 and S2.45 in WT-1 (lowest average energy rank) conformation.  The two residues interact via a hydrogen bond.  The heteroatom distance is indicated by the dotted line. The (S2.45-T3.46) hydrogen bond was found in five of our ten lowest energy protein structures after Molecular Dynamics (MD) annealing (20) on just the side chains of the two residues.  This hydrogen bond is especially important because it involves the residue, T3.46, selected for mutation.























Figure S2, related to Figure 3.  Effect of the amino acid at position 3.46 on the helical interactions in the human CB1 receptor. 
(A)	Comparison of the T3.46A model versus the WT homology model (based on the T3.46A conformation). 
(B)	Comparison of the WT model versus the T3.46I homology model (based on WT conformation). 
In each case, the residue (T in (A) or I in (B)) is too large for their respective positions, which explains why the protein structures must change to accommodate the mutants.




Figure S3, related to Figure 4.  Prediction and experimental verification of receptor stabilities.
(A)	Average interhelical energy for T3.46A, WT, T3.46I, T3.46A/R2.37Q, and T3.46A/R2.37A receptors.  Diagram comparing the interhelical energies (average of the charged and neutralized interhelical energy scores) and the state of activation for the predicted ten lowest average energy bundles for each receptor (T3.46A (blue), T3.46A/R2.37A (green), T3.46A/R2.37Q (yellow), WT (red), and T3.46I (gray)) that are shown in Table SII and Table I.  T3.46A has the TM2+TM6, TM3+TM6, and TM3+TM4 salt-bridges.  WT has the TM2+TM3, TM3+TM6, and TM3+TM4 salt-bridges.  T3.46I has the TM2+TM3 and TM5+TM6 salt-bridges.
(B)	Thermal stability of the CB1 T3.46A, WT, and T3.46I receptors. The membrane prepared from HEK293 cells expressing the WT or mutant receptors was incubated at the indicated temperature for 30 minutes followed by cooling on ice as described in Section S6.3. The residual binding capacity after heating the receptor relative to control was measured using [3H]CP55940.  The data are presented as the loss of [3H]CP55940 binding relative to the control sample for WT (), T3.46I (), T3.46A (),T3.46A/R2.37A (),T3.46A/R2.37QA (),  receptors. Each data point represents the mean  S.E.M. of three independent experiments performed in duplicate.
(C)	Relation of Tm and the average interhelical energy for CB1 T3.46A, T3.46A/R2.37A, T3.46A/R2.37Q, WT, and T3.46I receptors.  One conformation with the lowest average interhelical energy represents each receptor.  The predicted energies are plotted against the experimental Tm quantities.  An R2 value of 0.8251 indicates there is good correlation between the two.  The line indicates the trend.
























Figure S4, related to Figures 2-4. Effect of the proline residue on the shapes of TM6 (A) and TM7 (B). The helical backbone is shown in cyan, while the proline alpha-carbon atoms are brown spheres, and the (i-3) and (i-4) residue -carbon’s are lavender spheres. The axes and bend, wobble, and face shift angles are labeled in the same way as in Ref. (55).
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